Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
2.45% $4.18
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 130.35 mill |
EPS: | -0.0400 |
P/E: | -104.50 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 270.42 mill |
Avg Daily Volume: | 2.93 mill |
RATING 2024-04-19 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Buy | |
DE: | Strong Sell | |
P/E: | Strong Buy | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -104.50 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-17.78x |
Company: PE -104.50 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 3.93 - 4.43 ( +/- 5.98%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Sabella Lauren M | Sell | 17 084 | Common Stock, $.01 Par Value |
2024-02-04 | Tross Stuart A | Buy | 15 290 | Common Stock, $0.01 Par Value |
2023-12-31 | Tross Stuart A | Buy | 1 006 | Common Stock, $0.01 Par Value |
2023-06-30 | Tross Stuart A | Buy | 4 012 | Common Stock, $0.01 Par Value |
2024-02-04 | Blank Burkhard | Buy | 152 905 | Common Stock, $0.01 Par Value |
INSIDER POWER |
---|
30.59 |
Last 96 transactions |
Buy: 5 265 399 | Sell: 2 722 728 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.18 (2.45% ) |
Volume | 1.797 mill |
Avg. Vol. | 2.93 mill |
% of Avg. Vol | 61.25 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $3.44 | N/A | Active |
---|
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.